Non-invasive plasma treatment for HPV infections
Official title: Treatment of Infections of the Cervix Uteri With High- and Low-risk Variants of the Human Papillomavirus Using Non-invasive Physical Plasma
Run by University Hospital Tuebingen · NCT06291311 · Data updated 2026-11-12
This study is testing a new non-invasive plasma treatment to see if it can help people clear HPV infections without causing any cervical issues.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 50 (estimated) |
| Sponsor | University Hospital Tuebingen Academic / other |
| Locations | 1 site (Tübingen) |
| Status | Recruiting |
| Started | December 27, 2023 |
| Main results expected | September 2026 |
| Study ends | December 2026 |
| Registry record updated | June 30, 2026 |
| Trial ID | NCT06291311 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with confirmed HPV infections and visible transformation zones on the cervix.
✕Probably not a fit
Patients with invasive disease or those with serious cardiovascular conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational clinical trial aims to evaluate the effectiveness of non-invasive physical plasma (NIPP) in eradicating HPV infections in patients without cervical dysplasia. Conducted at the University Hospital Tübingen, the study will involve obtaining tissue samples at defined intervals through minibiopsy to analyze the cellular, molecular, and immunological effects of the treatment. The trial will compare outcomes between patients receiving NIPP and a control group, utilizing various molecular biological, histological, and microscopic methods for analysis.
Why it matters
Potential benefit: If successful, this treatment could provide a non-invasive option for eradicating HPV infections, potentially reducing the risk of cervical cancer.
How similar studies have gone: While there is ongoing research into non-invasive treatments for HPV, this specific approach using NIPP is novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Inclusion criteria for NIPP treatment * Age ≥ 18 years * mRNA or DNA-based virus detection by smear (also external findings) * Clearly visible transformation zone of the cervix and margins of the lesions corresponding to T1/T2 * Written informed consent to participate in the study * Inclusion criteria for control group * Age ≥ 18 years * Swab-based mRNA or DNA-based virus detection (also external findings) * Clearly visible transformation zone of the cervix corresponding to T1/T2 * Written informed consent to participate in the study Exclusion criteria: The following exclusion criteria apply to both groups of patients (NIPP treatment and control group). * Transformation zone not fully visible * Evidence of invasive disease * Serious cardiovascular diseases
Where it's running
-
University Hospital Tuebingen, Department of Women's Health
Tübingen, Germany Recruiting
Study contacts
- Principal investigator: Martin Weiss, Dr. med. — University Hospital Tuebingen
- Study coordinator: Martin Weiss, Dr. med.
- Email: martin.weiss@med.uni-tuebingen.de
- Phone: +497071 29 82211
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
At-home HPV self-collection kits for cervical cancer screening
We are testing different ways to give at-home HPV self-collection kits to under-screened people aged 25–65 to see if more of them complete cervical cancer screening and follow-up.
-
CHW4CervixHealth: HPV self-collection kits with community health workers
This project will test whether giving self-collection HPV kits during community workshops led by community health workers helps increase screening among under-screened women aged 25–65 and will first compare kit results to clinical Pap smears.
-
Same-day HPV screen-and-treat for women with HIV in La Romana
This project will test whether offering same-day HPV screening and immediate treatment improves detection and treatment completion for Spanish-speaking women living with HIV in La Romana, Dominican Republic.
-
Using a portable colposcope for cervical cancer screening
This study is testing a portable device to help screen women for cervical cancer and HPV in Kenya, aiming to improve diagnosis and treatment options.
-
Investigating HPV and skin cancer risks in organ transplant recipients
This study is trying to see if organ transplant recipients have a higher risk of HPV infections and skin cancer compared to people with normal immune systems.
-
HPV vaccination and screening for cervical cancer in young women in Sweden
This study is testing whether giving the HPV vaccine and screening for cervical cancer at the same time can help young women in Sweden reduce HPV infections more quickly.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.